Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG. Issue 4 (7th April 2023)

• Record Type: Journal Article
• Authors: Franklin, Cindy; Mohr, Peter; Bluhm, Leonie; Meier, Friedegund; Garzarolli, Marlene; Weichenthal, Michael; Kähler, Katharina; Grimmelmann, Imke; Gutzmer, Ralf; Utikal, Jochen; Terheyden, Patrick; Herbst, Rudolf; Haferkamp, Sebastian; Pfoehler, Claudia; Forschner, Andrea; Leiter, Ulrike; Ziller, Fabian; Meiss, Frank; Ulrich, Jens; Kreuter, Alexander; Gebhardt, Christoffer; Welzel, Julia; Schilling, Bastian; Kaatz, Martin; Scharfetter-Kochanek, Karin; Dippel, Edgar; Nashan, Dorothee; Sachse, Michael; Weishaupt, Carsten; Löffler, Harald; Gambichler, Thilo; Loquai, Carmen; Heinzerling, Lucie; Grabbe, Stephan; Debus, Dirk; Schley, Gaston; Hassel, Jessica C; Weyandt, Gerhard; Trommer, Maike; Lodde, Georg; Placke, Jan-Malte; Zimmer, Lisa; Livingstone, Elisabeth; Becker, Jürgen Christian; Horn, Susanne; Schadendorf, Dirk; Ugurel, Selma;
• Is Part Of: Journal for immunotherapy of cancer. Volume 11:Issue 4(2023)
• Publication Date: 2023-04-07
• Subjects: melanoma; Cancer -- Immunotherapy -- Periodicals; Cancer -- Immunological aspects -- Periodicals; Tumors -- Immunological aspects -- Periodicals; Immunotherapy -- Periodicals; 616.99406105
• DOI: 10.1136/jitc-2022-005828
• Languages: English
• ISSNs: 2051-1426

Abstract

Abstract : Background: Despite the availability of effective systemic therapies, a significant number of advanced melanoma patients develops brain metastases. This study investigated differences in incidence and time to diagnosis of brain metastasis and survival outcomes dependent on the type of first-line therapy. Methods: Patients with metastatic, non-resectable melanoma (AJCCv8 stage IIIC–V) without brain metastasis at start of first-line therapy (1L-therapy) were identified from the prospective multicenter real-world skin cancer registry ADOREG. Study endpoints were incidence of brain metastasis, brain metastasis-free survival (BMFS), progression-free survival (PFS), and overall survival (OS). Results: Of 1704 patients, 916 were BRAF wild-type (BRAF wt ) and 788 were BRAF V600 mutant (BRAF mut ). Median follow-up time after start of 1L-therapy was 40.4 months. BRAF wt patients received 1L-therapy with immune checkpoint inhibitors (ICI) against CTLA-4+PD-1 (n=281) or PD-1 (n=544). In BRAF mut patients, 1L-therapy was ICI in 415 patients (CTLA-4+PD-1, n=108; PD-1, n=264), and BRAF+MEK targeted therapy (TT) in 373 patients. After 24 months, 1L-therapy with BRAF+MEK resulted in a higher incidence of brain metastasis compared with PD-1±CTLA-4 (BRAF+MEK, 30.3%; CTLA-4+PD-1, 22.2%; PD-1, 14.0%). In multivariate analysis, BRAF mut patients developed brain metastases earlier on 1L-therapy with BRAF+MEK than with PD-1±CTLA-4 (CTLA-4+PD-1: HR 0.560, 95% CI 0.332 to 0.945, p=0.030; PD-1: HR 0.575, 95% CI 0.372 to 0.888, p=0.013). Type of 1L-therapy, tumor stage, and age were independent prognostic factors for BMFS in BRAF mut patients. In BRAF wt patients, tumor stage was independently associated with longer BMFS; ECOG Performance status (ECOG-PS), lactate dehydrogenase (LDH), and tumor stage with OS. CTLA-4+PD-1 did not result in better BMFS, PFS, or OS than PD-1 in BRAF wt patients. For BRAF mut patients, multivariate Cox regression revealed ECOG-PS, type of 1L-therapy, tumor stage, and LDH as independent prognostic factors for PFS and OS. 1L-therapy with CTLA-4+PD-1 led to longer OS than PD-1 (HR 1.97, 95% CI 1.122 to 3.455, p=0.018) or BRAF+MEK (HR 2.41, 95% CI 1.432 to 4.054, p=0.001), without PD-1 being superior to BRAF+MEK. Conclusions: In BRAF mut patients 1L-therapy with PD-1±CTLA-4 ICI resulted in a delayed and less frequent development of brain metastasis compared with BRAF+MEK TT. 1L-therapy with CTLA-4+PD-1 showed superior OS compared with PD-1 and BRAF+MEK. In BRAF wt patients, no differences in brain metastasis and survival outcomes were detected for CTLA-4+PD-1 compared with PD-1.